Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

A medspa playbook to turn attention into bookings—clear pages, local SEO, and one-screen scheduling. Start booking more clients today!

Data to be featured in two oral presentations on December 8, 2025 - - Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...

The ASH abstract published today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the June 30 th, ...

Discover AMG's Q3 2025 earnings momentum—record alternative inflows, rising EBITDA, strategic BBH partnership, and optimistic 2026 growth outlook.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell ...

Data to be featured in two oral presentations on December 8, 2025 –– Broad development program assesses ziftomenib across diverse AML segments ...

Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts ? one oral and four poster ...

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile ...

Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will ...